Combinational Therapy to Boost the Market Size of Melanoma Cancer Market

Release Date: 08-Nov-2020

Researchers are inclined towards adding plasmid IL-12 (pIL-12-EP) agent tavokinogene telseplasmid to pembrolizumab (Keytruda) in order to develop a deep systemic response in patients having progressive antiandndash;PD-1andndash;refractory advanced melanoma. The drug Keytruda was given at 200 mg. The other drug pIL-12-EP was also given the enrolled patients. The primary aim of the study was to determine the objective response rate (ORR) by blinded independent review. Some of the secondary aims of the researchers involved in the respective study was to study duration of response (DOR), progression-free survival (PFS), immune PFS (iPFS), immune ORR, and overall survival (OS).


In 21.4% of the enrolled patients, there were BRAF mutations. It was concluded by the researchers that the addition of the drug pIL-12-EP to PD-1 antibody therapy led to high complete response rate in the patients as well as overall response rate. In 19% of the enrolled patients, stable disease was observed. Also, it was found by the researchers that the patients who received the drug Yervoy prior to the treatment achieved an overall high response rate. At last, it was concluded by the researchers that their respective clinical trial study was able to cause 100% reduction in the size of the tumor cells. The researchers involved in the respective study also demonstrated that the strategic approach of the ntratumoral delivery of plasmid DNA via electric gene transfer system has resulted in stimulated IL-12 level in the tumor cells without impacting IL-12 in the blood. Altogther the respective study shows the potential of the combination in getting approved by the regulatory bodies for commercial use.

Need custom market research solution? We can help you with that too.